peptidylprolyl isomerase A pseudogene 5Genealiases: []
Q-omics provides the consensus-scored PPIAP5 profile across patient tissues and cancer cell-line models. PPIAP5 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PPIAP5 is differentially expressed in 1, with the highest sampling consensus in LUAD. Additionally, PPIAP5 RNA expression shows 3,284 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, LUAD, and STAD as cancer lineages where PPIAP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPIAP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPIAP5 survival associations across molecular data types. PPIAP5 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPIAP5 RNA expression–survival associations across cancer types. High PPIAP5 expression shows unfavorable associations in UVM, MESO, STAD, ACC, LUAD and READ. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PPIAP5 RNA expression.
This table summarizes PPIAP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for PPIAP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPIAP5 shows higher tumor expression in LUAD. The LUAD box plot shows higher PPIAP5 RNA expression in tumor versus normal tissue (log2 FC = +0.054, t-test p = .014).
This table shows molecular features associated with PPIAP5 in patient tissues and cancer cell lines. In patient samples, PPIAP5 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
